T790M is a gatekeeper substitution in the EGFR kinase domain that increases the mutant receptor's affinity for ATP, outcompeting first- and second-generation inhibitors such as erlotinib and afatinib. The mutation does not itself hyperactivate kinase activity but sterically prevents TKI binding at pharmacologically achievable concentrations, explaining why osimertinib (a third-generation, T790M-selective, covalent inhibitor) was developed to circumvent it.

MET amplification restores downstream PI3K-AKT and MAPK signaling by coupling the MET receptor to ERBB3 (HER3), which acts as a preferred scaffold for PI3K-p85 recruitment. Because this bypass does not require EGFR kinase activity, it operates entirely independently of EGFR inhibitor binding, making tumors with MET amplification intrinsically resistant to EGFR TKIs used as monotherapy.

KRAS G12C inhibitors bind the GDP-bound inactive conformation via the switch-II pocket. Resistance arises through secondary mutations in this pocket (Y96D, H95D) that reposition the binding surface, through adaptive ERK reactivation mediated by wild-type HRAS and NRAS isoforms, and through PAK-driven MEK phosphorylation at Ser298, which re-engages MAPK signaling independently of KRAS. Acquired BRAF V600E and KRAS G12V alleles additionally reactivate MAPK entirely downstream of the G12C target.

SCLC transformation is a histologic conversion from EGFR-mutant adenocarcinoma to small cell lung cancer occurring in approximately 3 to 15% of resistant cases. It is strongly associated with bi-allelic inactivation of TP53 and RB1: RB1 loss releases E2F transcription factors and reduces NOTCH signaling, permitting a neuroendocrine transcriptional program to dominate and rendering the resulting SCLC phenotype insensitive to EGFR inhibition by loss of oncogene identity rather than by mutation.

TKI-induced cellular stress activates NF-kB signaling, which transcriptionally upregulates APOBEC3B, a cytidine deaminase that introduces C-to-U mutations preferentially at TC motifs. This therapy-induced mutational process accelerates the accumulation of de novo resistance variants during the course of treatment, converting therapeutic pressure itself into a mutagen and explaining why resistance complexity increases over successive lines of therapy.

Cancer-associated fibroblasts secrete IL-6 and HGF, providing paracrine survival signals that protect tumor cells from TKI-induced apoptosis. HGF binding to MET additionally induces a conformational shift in EGFR (detectable as a molecular weight increase from 170 to 185 kDa), potentiating bypass signaling. EGFR-TKI treatment also triggers cGAS-STING-mediated upregulation of immunosuppressive Galectin-9, while STAT1 and ETS1 drive TGFB1 and CCL5 expression to promote T-cell exhaustion in the tumor microenvironment.

Epithelial-to-mesenchymal transition rewires the transcriptional identity of tumor cells through ZEB1, ID1, and miR-200c loss, creating a survival state that does not depend on EGFR signaling for proliferation. ZEB1 additionally activates EMP3 transcription and the tumor cells recruit FGFR1-PI3K-AKT as an alternative survival input, so TKI binding to EGFR becomes largely irrelevant to cell viability in fully mesenchymal clones. Non-cell-autonomous propagation via exosomal miR-210-3p delivery further expands the EMT-resistant fraction without requiring additional somatic mutation in recipient cells.